Rofecoxib (Vioxx) voluntarily withdrawn from market

Sibbald, Barbara
October 2004
CMAJ: Canadian Medical Association Journal;10/26/2004, Vol. 171 Issue 9, p1027
Academic Journal
Reports on the voluntary worldwide removal of rofecoxib in the pharmaceutical market by Merck & Co. Inc. in September 2004. Findings of the Adenomatous Polyp Prevention of Vioxx clinical trial on the risks of the long-term usage of rofecoxib for patients; Comparison of the effects of rofecoxib and placebo on patients with recurring polyps; Applications of rofecoxib in Canada.


Related Articles

  • Finding the Lessons in Vioxx. Tolchin, Elizabeth // Drug Discovery & Development;Nov2004, Vol. 7 Issue 11, p23 

    Reports on the withdrawal of Merck and Co. Inc.'s Vioxx, an arthritis and acute pain medication, from the market. Role of Vioxx in increasing the risk for cardiovascular events after 18 months of treatment; Implications for drug approval and pharmaceutical industry.

  • Is Merck a Goner? Herper, Matt; Langreth, Robert; Fass, Allison // Forbes Global;11/1/2004, Vol. 7 Issue 19, p16 

    Focuses on the risk of the painkiller drug Vioxx from Merck & Co. Demand for investigation into the risk of Vioxx by doctors; Number of lawsuits filed against the company; Results of a trial on Vioxx.

  • Telcagepant failure gives Merck & Co. an unwanted headache.  // PharmaWatch: CNS;Sep2011, Vol. 10 Issue 9, p7 

    The article reports that discontinuation of Merck & Co. Inc.'s six-month Phase III clinical trial for its acute migraine therapy telcageplant has added to the company's problem. Based on its financial update for the second quarter of 2011, the company plans to reduce its workforce by 12% until...

  • Merck and Lundbeck: Sanofi set to benefit from drug failure.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p15 

    The article reports that the drug gaboxadol has not been found to be effective in the treatment of insomnia. It causes side effects such as hallucinations, dizziness and vomiting when administered at only twice the recommended dose. This was revealed by Phase III trials of the drug which is...

  • FDA's Drug Safety Initiative: Protecting investors more than patients? McKinnie, Jason // Healthcare Purchasing News;Apr2005, Vol. 29 Issue 4, p68 

    Argues that the 2005 Drug Safety Initiative of the U.S. Food and Drugs Administration (FDA) protects investors more than the public. Areas of scrutiny in FDA and pharmaceutical companies that arose from the recall of the arthritis and acute pain drug Vioxx from Merck; Cardiovascular risk of...

  • Postmarketing Monitoring of Intussusception After RotaTeq Vaccination -- United States, February 1, 2006-February 15, 2007. Belongia, E.; Izurieta, H.; Braun, M. M.; Ball, R.; Haber, P.; Baggs, J.; Weintraub, E.; Gargiullo, P.; Vellozzi, C.; Iskander, J.; Patel, M.; Parashar, U.; Cortese, M. // MMWR: Morbidity & Mortality Weekly Report;3/16/2007, Vol. 56 Issue 10, p218 

    The article presents data from the postmarketing monitoring of intussusception events after RotaTeq vaccination in the U.S. from February 1, 2006 to February 15, 2007. It details all the intussusception reports received by the Vaccine Adverse Event Reporting System during the period. It...

  • Gold Standards in Pharmacovigilance: The Use of Definitive Anecdotal Reports of Adverse Drug Reactions as Pure Gold and High-Grade Ore. Hauben, Manfred; Aronson, Jeffrey K. // Drug Safety;2007, Vol. 30 Issue 8, p645 

    Anecdotal reports of adverse drug reactions are generally regarded as being of poor evidential quality. This is especially relevant for postmarketing drug safety surveillance, which relies heavily on spontaneous anecdotal reports. The numerous limitations of spontaneous reports cannot be...

  • To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Filler, Guido; Lepage, Nathalie // Pediatric Nephrology;Sep2004, Vol. 19 Issue 9, p962 

    Within a short period, we have witnessed a dramatic increase in the use of mycophenolate mofetil (MMF) in pediatric renal transplantation, with the drug often replacing azathioprine in combination with calcineurin inhibitor therapy. When the drug was introduced, the manufacturer considered...

  • Forum.  // Pharmaceutical Medicine - New Zealand;Apr2015, Vol. 29 Issue 2, p113 

    This section offers news briefs concerning the pharmaceutical industry, as of April 2015. A new guide to support the implementation of a new international standard on adverse event (AE) monitoring in the European Union was published by the European Medicines Agency (EMA). Bhutan and Bangladesh...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics